8-K: GRI Bio Implements 1-for-28 Reverse Stock Split for Nasdaq Compliance

GRI Bio, Inc. announced a 1-for-28 reverse stock split to increase its per share trading price and regain Nasdaq listing compliance.

Summary

• GRI Bio, Inc. (NASDAQ: GRI) is implementing a 1-for-28 reverse stock split of its common stock.
• The reverse stock split will legally take effect at 4:01 p.m. Eastern Time on January 23, 2026.
• Shares are expected to begin trading on a post-split adjusted basis on The Nasdaq Capital Market on January 26, 2026, under the current ticker symbol GRI.
• The primary purpose is to increase the per share trading price to regain compliance with Nasdaq's minimum bid price requirement.
• Every twenty-eight (28) shares of common stock outstanding will automatically convert into one (1) share.
• No fractional shares will be issued; stockholders will receive a cash payment based on the closing sale price on January 23, 2026.
• The number of outstanding common shares will reduce from approximately 15,016,434 (as of January 20, 2026) to approximately 536,301.
• The total authorized number of shares (250,000,000 Common, 10,000,000 Preferred) and the par value ($0.0001) will remain unchanged.
• Proportional adjustments will be made to outstanding stock options, warrants, convertible securities, and stock incentive plans.

Sentiment

Score: 3

Explanation: A reverse stock split, while necessary for Nasdaq compliance, often signals underlying challenges with the company's stock performance and can be viewed negatively by the market. It does not improve fundamental value, but prevents delisting, which is a positive for continued trading.

Positives

• Aims to regain compliance with Nasdaq's minimum bid price requirement, preventing potential delisting.

Negatives

• Reverse stock splits often indicate a company's stock price has fallen significantly, potentially signaling underlying financial or operational challenges.
• Can be perceived negatively by investors, potentially leading to further selling pressure.
• Does not fundamentally change the company's market capitalization or intrinsic value.

Risks

• Inability to maintain the listing of the Company's common stock on Nasdaq and to comply with applicable listing requirements.
• Changes in applicable laws or regulations.
• Inability of the Company to raise financing in the future.
• Success, cost, and timing of the Company's product development activities.
• Inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product.
• Inability of the Company to identify, in-license, or acquire additional technology.
• Inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing.
• Size and growth potential of the markets for the Company's products and services, and their respective ability to serve those markets, either alone or in partnership with others.
• Inaccuracy in the Company's estimates regarding expenses, future revenue, capital requirements, and needs for and the ability to obtain additional financing.
• Company's ability to protect and enforce its intellectual property portfolio, including any newly issued patents.
• Other risks and uncertainties indicated from time to time in the Company's filings with the U.S. Securities and Exchange Commission (the SEC), including the risks and uncertainties described in the Risk Factors section of the Company's most recent Annual Report on Form 10-K filed with the SEC on March 14, 2025, and subsequently filed reports.

Future Outlook

The Company anticipates that the reverse stock split will increase its per share trading price, enabling it to regain compliance with The Nasdaq Capital Market's minimum bid price requirement. The Company also continues to focus on the development and commercialization of its product candidates, including GRI-0621 for idiopathic pulmonary fibrosis and novel type 2 diverse NKT agonists for systemic lupus erythematosus.

Management Comments

• The Reverse Split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Industry Context

Reverse stock splits are a common strategy employed by companies, particularly in the biotechnology sector, when their stock price falls below exchange minimums. This action is typically taken to maintain listing compliance on major exchanges like Nasdaq, which have minimum bid price requirements. While it addresses a technical listing requirement, it does not inherently change the company's fundamental value or operational performance. Other biotech companies facing similar challenges often resort to reverse splits to avoid delisting, which can severely impact liquidity and investor confidence.

Corporate Governance

Stakeholder Impact

• Shareholders: Will hold fewer shares but with a proportionally higher per-share price. Those with fractional shares will receive cash. The primary impact is the potential for continued Nasdaq listing, which preserves liquidity. However, reverse splits can sometimes lead to further stock price declines due to negative market perception.
• Employees (with stock options/incentives): Stock options, warrants, and convertible securities will be proportionally adjusted in terms of exercise price and number of shares, maintaining their intrinsic value.
• Nasdaq: The action is intended to bring the company into compliance with Nasdaq's minimum bid price requirement.

Next Steps

• Shares to begin trading on a post-split adjusted basis on The Nasdaq Capital Market on January 26, 2026.
• Transfer agent (Broadridge Corporate Issuers Solutions, Inc.) will send instructions for exchanging physical stock certificates for new electronic or physical certificates.
• Continue development and commercialization of product candidates, including GRI-0621 and novel type 2 diverse NKT agonists.

Key Dates

Recommendation

While a reverse stock split is often a negative signal, this action is a necessary step for GRI Bio to maintain its Nasdaq listing, which is crucial for liquidity and investor access. The split itself does not alter the company's fundamental value or business prospects. Investors should hold to observe if the company can sustain Nasdaq compliance and if its underlying biotechnology pipeline (GRI-0621 for IPF, NKT agonists for SLE) shows promising developments. A 'sell' would be premature without further negative news on the pipeline or continued non-compliance issues post-split, and a 'buy' is not warranted given the underlying stock performance issues that necessitated the split.

Keywords

GRI Bio, Reverse Stock Split, Nasdaq Compliance, Biotechnology, GRI, Stock Split, SEC Filing, 8-K, Common Stock, Share Price